Company Profile:

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Recent News:

The company reported net loss for the fourth quarter and year ended December 31, 2016 was $29.6 million, or $0.44 per share, and $91.1 million, or $1.40 per share, respectively.

Aduro Biotech, Inc. announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.

VP Blaine Templeman sold 3,785 shares of the business’s stock in a transaction dated Wednesday, January 11th, 2017. The stock was sold at an average price of $11.95, for a total transaction of $45,230.75.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

ADRO’s strengths can be seen in its strong growth compared with its peers. Technical indicators signal the bullish signs, as the %K value rises above the %D and the values are far under 80. RSI(14) stands at 51.88 with positive bias. We rate Aduro BioTech, Inc. (ADRO) a STRONG BUY.